Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292794 · ClinicalTrials.gov registry record · NA
Use of CereGate Therapy for Freezing of Gait in PD
A NA study of Parkinson Disease and Deep Brain Stimulation, sponsored by CereGate.
- Recruiting
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 7
- Study locations
NCT05292794: Recruiting NA study of Parkinson Disease and Deep Brain Stimulation, sponsored by CereGate.
NCT05292794 is a NA study of Parkinson Disease and Deep Brain Stimulation that is actively recruiting participants, run by CereGate. The registered enrollment target is 41 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05292794, a NA study of Parkinson Disease and Deep Brain Stimulation, is actively recruiting participants, sponsored by CereGate.
- RECRUITING
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
Primary Outcome
The primary objective of this study is to determine whether adjunctive use of CereGate therapy reduces Freezing of Gait in participants diagnosed with Parkinson's Disease in the ON-MEDS/ON-DBS state. The primary efficacy endpoint for this study is the mean percent change in excess arrhythmicity during Turning and Barriers Course Figures of 8 (TBC-F8) while ON-med/ON-DBS, pre-CG therapy to post-CG Therapy follow-up. The Opal wearable inertial measurement sensor (APDM Inc., Portland, OR) will be u
Conditions Studied
Interventions
- DEVICE CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Study Locations (7)
California
- Kaiser Permanente, KPNC Comprehensive Movement Disorders Program - Redwood City
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- University of Miami - Miami
Illinois
- Northwestern University - Chicago
North Carolina
- Wake Forest University - Winston-Salem
Tennessee
- Vanderbilt University Medical Center - Nashville
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2027-07 |
| Phase | NA |
What NCT05292794 shows while recruiting
NCT05292794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which CereGate Software; BSN cDBS Programmer; BSN Burst Programmer is the first listed.
NCT05292794 lists 7 locations in 7 states (California, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT05292794 about?
NCT05292794 is a clinical study titled "Use of CereGate Therapy for Freezing of Gait in PD". A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
What is the current status of trial NCT05292794?
This trial is currently recruiting. It is a NA study. The enrollment target is 41 participants. The study started on 2022-04-18. Estimated completion is 2027-07.
What conditions does trial NCT05292794 study?
This clinical trial studies the following conditions: Parkinson Disease, Deep Brain Stimulation, Freezing of Gait.
What interventions are being tested in trial NCT05292794?
The interventions under investigation include: CereGate Software; BSN cDBS Programmer; BSN Burst Programmer (DEVICE).
Who is sponsoring clinical trial NCT05292794?
This trial is sponsored by CereGate, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05292794 being conducted?
This trial has 7 study locations across California, Colorado, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05292794's enrollment target sits among peer trials
41 171st of 297 higher than 126 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI